Leerink Partnrs Predicts Revvity’s Q4 Earnings (NYSE:RVTY)

Revvity, Inc. (NYSE:RVTY) – Equities research analysts at Leerink Partnrs decreased their Q4 2024 EPS estimates for shares of Revvity in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of $1.37 for the quarter, down from their prior forecast of $1.38. The consensus estimate for Revvity’s current full-year earnings is $4.84 per share. Leerink Partnrs also issued estimates for Revvity’s FY2025 earnings at $5.08 EPS and FY2026 earnings at $5.72 EPS.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.15. The firm had revenue of $684.10 million during the quarter, compared to analyst estimates of $679.66 million. Revvity had a return on equity of 7.42% and a net margin of 9.34%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $1.18 EPS.

Several other equities analysts have also recently commented on the stock. TD Cowen boosted their price target on shares of Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Leerink Partners increased their price target on Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Raymond James cut their price objective on Revvity from $146.00 to $140.00 and set an “outperform” rating for the company in a research report on Tuesday. Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price for the company. in a research note on Friday, January 10th. Finally, Barclays lowered their price objective on Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $132.00.

Revvity Stock Up 4.7 %

Shares of NYSE:RVTY opened at $123.97 on Wednesday. The company has a market cap of $15.09 billion, a PE ratio of 59.89, a price-to-earnings-growth ratio of 3.50 and a beta of 1.03. The firm has a 50 day simple moving average of $114.89 and a 200 day simple moving average of $117.77. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. Revvity has a 52 week low of $97.32 and a 52 week high of $129.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Empirical Finance LLC raised its position in shares of Revvity by 2.0% in the 3rd quarter. Empirical Finance LLC now owns 4,237 shares of the company’s stock valued at $541,000 after acquiring an additional 85 shares during the period. CX Institutional grew its holdings in shares of Revvity by 1.1% in the 3rd quarter. CX Institutional now owns 7,984 shares of the company’s stock valued at $1,020,000 after acquiring an additional 86 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Revvity by 2.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company’s stock worth $470,000 after purchasing an additional 100 shares during the last quarter. HB Wealth Management LLC raised its position in Revvity by 4.6% during the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company’s stock worth $266,000 after acquiring an additional 104 shares in the last quarter. Finally, Westside Investment Management Inc. raised its holdings in shares of Revvity by 0.8% in the 4th quarter. Westside Investment Management Inc. now owns 14,363 shares of the company’s stock valued at $1,603,000 after purchasing an additional 108 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insiders Place Their Bets

In other news, insider Tajinder S. Vohra sold 5,492 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.60% of the company’s stock.

Revvity declared that its board has approved a share buyback program on Monday, November 4th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 6.5% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. Revvity’s dividend payout ratio is 13.53%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.